GEN Exclusives

More »

GEN News Highlights

More »
Dec 5, 2011

Even Split on Whether Federal Circuit Will Change Akamai, McKesson Decisions

  • Voters are evenly divided, at 42.9%, on whether they think the Federal Circuit will change the standing infringement decisions for the Akamai and McKesson cases as a result of en banc arguments that occurred last month. The remaining 14.3% of respondents were undecided.

    Biopharma industry stakeholders are seeking clearer direction on when patents can be considered jointly infringed. Earlier this year, separate Federal Circuit panels held there was no viable legal theory to support findings that defendants in the two cases engaged in joint infringement, despite a contractual relationship in Akamai Technologies, Inc. v. Limelight Networks, Inc. and a doctor/patient relationship in McKesson Technologies Inc. v. Epic System Corp. Akamai and McKesson have won support from BIO, PhRMA, and Myriad Genetics, which all assert that current stipulations of joint infringement could be detrimental to personalized medicine.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »